FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136393837> ?p ?o ?g. }

• W3136393837 endingPage "146" @default.
• W3136393837 startingPage "144" @default.
• W3136393837 abstract "Pneumothorax (PNX) and pneumomediastinum (PMD) have been frequently observed in mechanically ventilated patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS), with a reported rate up to 24% [[1]Belletti A. Palumbo D. Zangrillo A. et al.Predictors of pneumothorax/pneumomediastinum in mechanically ventilated COVID-19 patients.J Cardiothorac Vasc Anesth. 2021; (In press)https://doi.org/10.1053/j.jvca.2021.02.008Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar]. No study has evaluated so far the exact rate of these events in non-intubated COVID-19 patients. We therefore decided to perform an observational study to investigate the rate of PNX/PMD in non-intubated COVID-19 patients and to compare the rate of PNX/PMN between patients admitted during the first and second Italian pandemic wave. Under our Institutional Review Board-approved protocol (protocol number 34/int/2020; ClinicalTrials.gov no. NCT04318366), we identified all patients with pneumothorax and/or pneumomediastinum documented at chest X-ray or computed tomography (CT) between March 1st, 2020 and June 1st, 2020 (first Italian wave) and between October 1st, 2020 and January 1st, 2021 (second Italian wave) (Fig. 1). Patients were included in the analysis if not invasively ventilated before PNX/PMD diagnosis. Details on hospital organization and clinical management have been previously published [2Zangrillo A. Beretta L. Scandroglio A.M. et al.Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy.Crit Care Resusc. 2020; 22: 200-211PubMed Google Scholar, 3Ramirez G.A. Bozzolo E.P. Castelli E. et al.Continuous positive airway pressure and pronation outside the intensive care unit in COVID 19 ARDS.Minerva Med. 2020; (In press)https://doi.org/10.23736/S0026-4806.20.06952-9Crossref PubMed Scopus (15) Google Scholar, 4Zangrillo A. Beretta L. Silvani P. et al.Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency.Crit Care Resusc. 2020; 22: 91-94PubMed Google Scholar, 5Sartini C. Tresoldi M. Scarpellini P. et al.Respiratory Parameters in Patients with COVID-19 after Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit.JAMA. 2020; 323: 2338-2340https://doi.org/10.1001/jama.2020.7861Crossref PubMed Scopus (210) Google Scholar]. The main change in patients’ management between first and second pandemic wave was the administration of dexamethasone to all patients requiring oxygen supplementation during the second wave and the avoidance of hydroxychloroquine [[6]Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.N Engl J Med. 2021; 384: 693-704https://doi.org/10.1056/nejmoa2021436Crossref PubMed Scopus (0) Google Scholar]. We collected data as per Table 1. Categorical variables are expressed as numbers and percentages; continuous variables are presented as median and interquartile range. Continuous measures were compared using Wilcoxon matched pairs signed rank test, while dichotomous data were compared using χ2 or Fisher's exact. Two-sided p-value < 0.05 defined statistical significance.Table 1Patients’ characteristics and treatment details. .VariableFirst wave(N = 1)Second wave(N = 13)Age, years7572 (65 – 76)Male sexMale12 (92.3)CPAPYes7 (53.8)Steroid therapy-Dexamethasone-PrednisoneNo13 (100)-12 (92.3)-1 (7.7)LMWH (4000 IU enoxaparin)Yes13 (100)Antibiotic therapyYes9 (69.2)HCQ (400 mg daily)Yes0 (0.0)Biologics-Tocilizumab (400 mg)-Anakinra (10 mg/kg)No5 (38.5)-1 (7.7)-4 (30.8)Comorbidities-COPD-ILD-DM-CancerYes: -Yes-No-No-No3 (23.1)-1 (7.7)-0 (0.0)-1 (7.7)-2 (13.4)Continuous variables are presented as median and interquartile range, while categorical variables are presented as number and percentages.CPAP: continuous positive airway pressure; COPD: chronic obstructive pulmonary disease; DM: type-2 diabetes mellitus; HCQ: hydroxychloroquine; ILD: interstitial lung disease; IU: international units; LMWH: low molecular weight heparin. Open table in a new tab Continuous variables are presented as median and interquartile range, while categorical variables are presented as number and percentages. CPAP: continuous positive airway pressure; COPD: chronic obstructive pulmonary disease; DM: type-2 diabetes mellitus; HCQ: hydroxychloroquine; ILD: interstitial lung disease; IU: international units; LMWH: low molecular weight heparin. All the 1151 patients of the first wave and 1484 patients of the second wave did multiple chest X-ray examinations and 813 non-intubated COVID-19 patients underwent at least one CT scan (418, first pandemic wave; 395, second pandemic wave). Fourteen non-intubated patients with radiologically proven PNX/PMD were identified: one patient during the first wave and 13 during the second wave (p = 0.005 when using all patients at denominator and p<0.001 when using only patients who underwent CT scan at denominator). Specifically, eight patients had PMD, two PNX, whereas the remaining three had both. Patients’ characteristics are summarized in Table 1. At the time of PNX/PMD development, eight patients were on CPAP, whereas six patients were on supplemental oxygen therapy only. All but the patient of the first wave were on steroid therapy (dexamethasone 6 mg daily in 12 cases and prednisone 60 mg daily in one case, p = 0.071). Median time from symptoms onset to PNX/PMD was 18 (17–24.5) days; median time form corticosteroid start to PNX/PMD was 15 (13–17) days. After PNX/PMD onset, four (29%) patients were admitted to ICU and seven (50%) patients died. The rate of PNX/PMD in non-intubated COVID-19 was significantly higher in the second pandemic wave as compared with the first pandemic wave. To the best of our knowledge, this is the first report comparing incidence of PNX/PMD in non-intubated COVID-19 ARDS patients in the first and second pandemic wave. As the only difference in treatment between the two waves was dexamethasone administration and hydroxychloroquine avoidance, it could be hypothesized that dexamethasone might have induced lung frailty and increased the risk of PNX/PMD, as already suggested in patients with interstitial inflammatory lung diseases [[7]Nishimoto K. Fujisawa T. Yoshimura K. et al.Pneumothorax in connective tissue disease-associated interstitial lung disease.PLoS ONE. 2020; 15https://doi.org/10.1371/journal.pone.0235624Crossref Scopus (10) Google Scholar]. Future studies are needed to confirm a different rate of PNX/PMD when using or not corticosteroids in COVID-19 patients. None" @default.
• W3136393837 created "2021-03-29" @default.
• W3136393837 creator A5022352601 @default.
• W3136393837 creator A5027512145 @default.
• W3136393837 creator A5032708589 @default.
• W3136393837 creator A5035626409 @default.
• W3136393837 creator A5065299644 @default.
• W3136393837 creator A5072968608 @default.
• W3136393837 creator A5088912880 @default.
• W3136393837 date "2021-06-01" @default.
• W3136393837 modified "2023-10-17" @default.
• W3136393837 title "Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave" @default.
• W3136393837 cites W3024584839 @default.
• W3136393837 cites W3039140921 @default.
• W3136393837 cites W3090592448 @default.
• W3136393837 cites W3126364578 @default.
• W3136393837 cites W4210642183 @default.
• W3136393837 doi "https://doi.org/10.1016/j.ejim.2021.03.018" @default.
• W3136393837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7972796" @default.
• W3136393837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33820685" @default.
• W3136393837 hasPublicationYear "2021" @default.
• W3136393837 type Work @default.
• W3136393837 sameAs 3136393837 @default.
• W3136393837 citedByCount "28" @default.
• W3136393837 countsByYear W31363938372021 @default.
• W3136393837 countsByYear W31363938372022 @default.
• W3136393837 countsByYear W31363938372023 @default.
• W3136393837 crossrefType "journal-article" @default.
• W3136393837 hasAuthorship W3136393837A5022352601 @default.
• W3136393837 hasAuthorship W3136393837A5027512145 @default.
• W3136393837 hasAuthorship W3136393837A5032708589 @default.
• W3136393837 hasAuthorship W3136393837A5035626409 @default.
• W3136393837 hasAuthorship W3136393837A5065299644 @default.
• W3136393837 hasAuthorship W3136393837A5072968608 @default.
• W3136393837 hasAuthorship W3136393837A5088912880 @default.
• W3136393837 hasBestOaLocation W31363938371 @default.
• W3136393837 hasConcept C118552586 @default.
• W3136393837 hasConcept C126322002 @default.
• W3136393837 hasConcept C141071460 @default.
• W3136393837 hasConcept C179755657 @default.
• W3136393837 hasConcept C2776348555 @default.
• W3136393837 hasConcept C2777131390 @default.
• W3136393837 hasConcept C2777714996 @default.
• W3136393837 hasConcept C2778329176 @default.
• W3136393837 hasConcept C2779134260 @default.
• W3136393837 hasConcept C2780724011 @default.
• W3136393837 hasConcept C3008058167 @default.
• W3136393837 hasConcept C524204448 @default.
• W3136393837 hasConcept C71924100 @default.
• W3136393837 hasConcept C89623803 @default.
• W3136393837 hasConceptScore W3136393837C118552586 @default.
• W3136393837 hasConceptScore W3136393837C126322002 @default.
• W3136393837 hasConceptScore W3136393837C141071460 @default.
• W3136393837 hasConceptScore W3136393837C179755657 @default.
• W3136393837 hasConceptScore W3136393837C2776348555 @default.
• W3136393837 hasConceptScore W3136393837C2777131390 @default.
• W3136393837 hasConceptScore W3136393837C2777714996 @default.
• W3136393837 hasConceptScore W3136393837C2778329176 @default.
• W3136393837 hasConceptScore W3136393837C2779134260 @default.
• W3136393837 hasConceptScore W3136393837C2780724011 @default.
• W3136393837 hasConceptScore W3136393837C3008058167 @default.
• W3136393837 hasConceptScore W3136393837C524204448 @default.
• W3136393837 hasConceptScore W3136393837C71924100 @default.
• W3136393837 hasConceptScore W3136393837C89623803 @default.
• W3136393837 hasLocation W31363938371 @default.
• W3136393837 hasLocation W31363938372 @default.
• W3136393837 hasOpenAccess W3136393837 @default.
• W3136393837 hasPrimaryLocation W31363938371 @default.
• W3136393837 hasRelatedWork W1873645693 @default.
• W3136393837 hasRelatedWork W1996319417 @default.
• W3136393837 hasRelatedWork W2106621355 @default.
• W3136393837 hasRelatedWork W2412917519 @default.
• W3136393837 hasRelatedWork W3084049187 @default.
• W3136393837 hasRelatedWork W3174770936 @default.
• W3136393837 hasRelatedWork W3197456510 @default.
• W3136393837 hasRelatedWork W4210890218 @default.
• W3136393837 hasRelatedWork W4307036623 @default.
• W3136393837 hasRelatedWork W4321608534 @default.
• W3136393837 hasVolume "88" @default.
• W3136393837 isParatext "false" @default.
• W3136393837 isRetracted "false" @default.
• W3136393837 magId "3136393837" @default.
• W3136393837 workType "article" @default.